Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 2, 2008, Pages 135-140

  Terrab, Abdel ^a   Pawlak, Dan ^a   Spaay, Pat ^a   Hoppensteadt, Debra ^b   Fareed, Jawed ^b  

^a King Pharmaceuticals   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Bovine thrombin; Factor Va; Topical hemostat; Virus filtration; Western blot

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; THROMBIN;

ARTICLE; BLOOD CLOTTING DISORDER; CHROMATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FILTRATION; HUMAN; IMMUNOGENICITY; MEMBRANE FILTER; NONHUMAN; PRIORITY JOURNAL; SWINE; TECHNIQUE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CATTLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VA; FILTRATION; THROMBIN; VIRUSES;

EID: 40549126579     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607308866     Document Type: Article

References (22)

1. Block J. Severe blood loss during spinal reconstructive procedures: the potential usefulness of topical hemostatic agents. Med Hypotheses. 2005 ; 65: 617-621.
2. Renkens KL Jr, Payner T., Leipzig T., et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001 ; 26: 1645-1650.
3. Sabel M., Stummer W. The use of local agents: surgicel and Surgifoam. Eur Spine J. 2004 ; 13: S97 - S101.
4. Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm. 2006 ; 63: 1244-1253.
5. Oz M., Rondinone JF, Shargill NS FloSeal Matrix: new generation topical hemostatic sealant. J Card Surg. 2003 ; 18: 486-493.
6. Bishop P., Lewis K., Schultz J., et al. Comparison of recombinant human thrombin and plasma-derived human α-thrombin. Semin Thromb Hemost. 2006 ; 32: 86-97.
7. Lundblad RL, Bradshaw RA, Gabriel D., et al. A review of the therapeutic uses of thrombin. Thromb Haemost. 2004 ; 91: 851-860.
8. Davie E., Kulman J. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006 ; 32: 3-15.
9. Yonemura H., Imamura T., Soejima K., et al. Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin. J Biochem (Tokyo). 2004 ; 135: 577-582.
10. Zehnder JL, Leung LL Immunological consequences of topical bovine thrombin. Am J Pathol. 2001 ; 159: 2371.
11. Schoenecker JG, Hauck RK, Mercer MC, et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose α1-3 galactose. J Clin Immunol. 2000 ; 20: 434-444.
12. Leung LL Perioperative evaluation of bleeding diathesis. Hematology Am Soc Hematol Educ Program. 2006: 457-461.
13. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001 ; 58: 710-719.
14. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005 ; 79: 1037-1038.
15. Sarfati MR, Dilorenzo DJ, Kraiss LW, et al. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004 ; 18: 349-51.
16. Suzuki K., Dahlback B., Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982 ; 257: 6556-6564.
17. Bollag DM, Rozycki MD, Edelstein SJ Immunoblotting. In: Henderson D, ed. Protein Methods. 2 nd ed. Wilmington, DL: Wiley-Liss Inc.; 1996: 195-227.
18. Tomizawa Y. Clinical benefits and risk analysis of topical hemostats: a review. J Artif Organs. 2005 ; 8: 137-142.
19. Cmolik BL, Spero JA, Magovern GJ, et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg. 1993 ; 105: 222-228.
20. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994 ; 45: 128-135.
21. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001 ; 233: 88-96.
22. Winterbottom N., Kuo JM, Nguyen K., et al. Antigenic response to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res Clin Exp Ther. 2002 ; 2: 1-12.